Grade: Pharmaceutical Grade

Factory Location: China

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Monthly Production Capacity: 500kg

Contract Manufacturing: CRO,CMO

Packaging Information: 5kg/drum

Delivery Lead Time: 15days

Sample Provided: no

Payment Terms: L/L

Function

Osimertinib is active against exon 19 deletions, exon 21 mutations, and also the exon 20 T790M mutations. It is preferentially selective for mutated EGFR, and therefore toxicity at therapeutic doses is lower than for first- and second-generation agents. Notably, osimertinib is able to cross the blood-brain barrier, making it active against disease in the CNS.